13 Comments
 

Not too familiar with the group and haven't heard much from the recently, but I believe they mainly work on MM mandates and compete against MMs like Baird and Piper Sandler. Would probably still peg them behind Piper Sandler after the TRS acquisition and Jefferies, and I think Baird it too new to have an accurate comparison.

That being said, I don't think they are close to competing with the Mid-tier RX groups like PWP, GHL, Gugg, Ducera, and they don't really play in the $1B+ space like the other guys.

 

Stopping the bleeding of MS god damn

But According to Reorg, by Most Retained Advisor:

1. HL

2. PJT

3. Evercore

4. MoCo

5. PWP

6. Laz

7. Jeff

8. CVP

9. Roth

10. Ducera

By Earnings:

1. HL

2. Roth

3. Seabury

4. PJT

5. MoCo

6. EVR

7. Laz

8. Gugg

9. Jeff

10. GLC

Skip a few to 17. Where Ducera is

From Reorg's 2022 Restructuring League Tables

 
Most Helpful

I think you're getting MS'ed because of some of the somewhat inaccurate descriptions. Also should note that RX league tables aren't nearly as reflective as standings because of the limited number of engagements they capture.

Greenhill's deal flow will probably be fine as long as Augustine is there - he brings in a lot of sponsor-related deal flow including portco rx and recaps that aren't necessarily reflected in league tables.

Ducera does a lot of creditor work but has also been putting in quite a lot of debtor-related work (was just on Wework), and I've heard things are busier than ever there.

Jefferies RX is very big in the UCC space (which they've been mostly happy to stay in), and also do a lot of work with the LevFin team (somewhat like the RX engagements you see at balance sheet banks)

PWP's senior team is anything but shrinking, they've poached RX seniors like crazy over the past 5 years and Bruce has led the rebuild very well. RX deal flow there hasn't slowed down and would argue that PWP doesn't even belong in the conversation with the rest of the firms you listed.

 

Deleniti voluptatem enim omnis repudiandae ab dicta enim quia. Numquam non explicabo aspernatur in quaerat qui. Autem voluptatem sapiente quo officiis.

Non quis quia similique molestiae nobis nisi harum. Aliquid dolorum rerum porro assumenda earum a nostrum. Ut nihil quas odit iste eum.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (16) $429
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”